echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Acta Neuropathologica: Multigroup molecular maps reveal potential targeting abnormalities common to multiple histology of brain metastasis

    Acta Neuropathologica: Multigroup molecular maps reveal potential targeting abnormalities common to multiple histology of brain metastasis

    • Last Update: 2021-02-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Brain metastasis (BM) is a common and fatal complication of systemic malignancies, which often occurs in 10-30% of adult cancer patients.
    The inherent limitations of surgical access and drug penetration within the central nervous system (CNS) further complicate the treatment of BM, and these limitations become more clinically relevant as the treatment of primary or other transcranial dispersal malignancies continues to improve.
    BM is most commonly found in relatively narrow tumor cross-sections, including lung, breast and kidney cancers, and malignant melanomas, suggesting that common biological mechanisms play a fundamental role in common brain metastatic tumor types.
    To identify and describe these mechanisms, the study used all-exon sequencing, mRN-seq, and introphic protein array analysis to perform genomic, transcriptional, and proteomic analysis of lung, breast and renal cell carcinomas, including BM and patient-matched primary or extracranial metastasis tissue.
    Although no specific genomic changes were associated with BM, the correlation with cellular immunodeficiency, oxyphosphatation (OXPHOS) and typical carcinogenic signaling pathps, including inositol 3 kinase (PI3K) signals, was evident in a variety of tumor histology.
    multiple immunofluorescence analysis confirmed significant T-cell depletion in BM, indicating a fundamental change in the immune micro-environment.
    addition, functional studies using in vitro and in vivo models have shown that the oxidation metabolism in mouse BM models and brain metastasis derivatives is enhanced and sensitive to OXPHOS inhibition compared to the gene parent.
    , pathophysiological recombination of carcinogenic signals, cell metabolism and immune microencienties is a widespread feature of BM.
    further analysis of this biology could reveal promising targets for the development of treatments for BM caused by multiple systemic cancers.
    Fukumura, K., Malgulwar, P.B., Fischer, G.M. et al. Multi-omic molecular profiling reveals potentially targetable abnormalities shared across multiple histologies of brain metastasis. Acta Neuropathol (2021). MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.